Will psychedelics be available commonly in the near future?

Will psychedelics be available commonly in the near future?

Although it took almost two decades to manifest the fame of Alexander Fleming as the father of penicillin, the discovery profoundly influenced humanity. It’s remarkable that every single dose comes from a single cantaloupe originated in Peoria. Within a year of scraping mold, 100 million units are produced every month by American pharmaceutical companies.
The timing was chance, as medicine was in high demand during World War II. Since that time antibiotics have played a major role in medicine. That might change soon. Big Pharma has churned out three new strains per year, as Bill Bryson writes in his new book The Body: a Guide for Occupants, from 50 to ’80s. Now it releases one every year and continues to decline.

Why? We are antibiotic-resistant. The money is getting dry. Big Pharma would instead concentrate on life-long medications including statins and selective serotonin reduction inhibitors (SSRIs).
This profit-driven approach to medicine could be our undoing even beyond the dire question of the loss of antibiotics. No person should take a pill for life except in cases of medical need. For all the obviously beneficial qualities of SSRIs, they prove very ineffective (and sometimes really deadly) in the long run. Better solutions are available.

Join Paul Stamets, one of the world’s leading fungi experts. The mycologist has been attending the Joe Rogan Experience recently, where he discussed the benefits of mycelia. Stamets pointed out that early research evidence shows that “the neurogenic benefits from micro-dosing are greater than the neurogenic benefit of macrodosing.” In a discussion of psilocybin, psychedelic strains of the mushrooms that gained a great deal of attention lately for their therapeutic applications.
This is a large claim, but if it is true, it is important. The use of psilocybin and LSD protocols for productivité benefits has been increasingly relieved (in the hands of popular media) by technology staff.
The potential for psychedelics to treat depression and other mental health conditions is more important to the larger population. Contrary to current medicines, serotonergic psychedelics seem to “boot” some brain areas, leading to better mental health perspectives.

Researchers studied the effects of psychedelic truffles in the Netherlands (masses of mycelia containing psilocybin) for the microdosing test has been shown that psilocybin binds to serotonin 2A receptors, resulting in “enhanced cognitive mobility, increased associated learning and hippocampal neurogenesis.”
For this study, researchers didn’t use a control group, so that more research is needed as with the range of psychedelic research. We need it, however. The FDA aims to improve treatments for problems with chronic mental health.
In the meantime, the US Defense Department’s DARPA plan to reduce MDMA and Psilocybin hallucinating effects in the military for treating PTSD or anxiety. Maybe the agency should consult with Stemets to see how psychedelics and niacin (vitamin B3) have a beneficial effect.